Ruby Anne E. Deveras, MD; Craig M. Kessler, MD
Potential Financial Conflicts of Interest:Consultancies: R.A.E. Deveras, C.M. Kessler. Honoraria: C.M. Kessler.
Requests for Single Reprints: Ruby Anne E. Deveras, MD, Division of Hematology and Oncology, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007-2197; e-mail, email@example.com.
Current Author Addresses: Drs. Deveras and Kessler: Division of Hematology and Oncology, Georgetown University Medical Center, Lombardi Cancer Center, 3800 Reservoir Road NW, Washington, DC 20007-2197.
Author Contributions: Conception and design: R.A.E. Deveras.
Analysis and interpretation of the data: R.A.E. Deveras, C.M. Kessler.
Drafting of the article: R.A.E. Deveras.
Critical revision of the article for important intellectual content: C.M. Kessler.
Final approval of the article: C.M. Kessler.
Provision of study materials or patients: C.M. Kessler.
Collection and assembly of data: R.A.E. Deveras.
Deveras R., Kessler C.; Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate. Ann Intern Med. 2002;137:884-888. doi: 10.7326/0003-4819-137-11-200212030-00009
Download citation file:
Published: Ann Intern Med. 2002;137(11):884-888.
Bleeding associated with warfarin anticoagulation correlates directly to duration and degree of international normalized ratio (INR) elevation above the therapeutic range. Safe and rapid reversal of excessive anticoagulation is occasionally needed to treat or avoid hemorrhagic complications.
To evaluate the efficacy and safety of human recombinant factor VIIa (rFVIIa) concentrate in persons requiring rapid reversal of the effects of warfarin.
Uncontrolled case series.
Academic medical center.
13 patients with critically increased INRs requiring immediate reversal of warfarin-induced anticoagulation.
Prothrombin time and INR were measured before and after administration of varying doses of rFVIIa.
Critically prolonged INR and bleeding complications were treated successively and rapidly in all patients, regardless of rFVIIa dose (range, 15 to 90 Âµg/kg of body weight). Indications for use of rFVIIa included an INR greater than 10 in high-risk persons (n = 5), clinical hemorrhage (n = 4), and diagnostic or therapeutic procedures (n = 4).
Safe, rapid, and effective administration of rFVIIa corrects critically prolonged INRs and can avert or reverse bleeding associated with warfarin anticoagulation.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Infectious Disease, Coagulopathies, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only